Content

Welcome to the CJU website » LOG IN

HOW I DO IT


First Prev Page 1 of 1 Next Last
  • How I do it: Apalutamide use in non-metastatic castrate resistant prostate cancer

    Moul W. Judd, MD Division of Urology, Department of Surgery and Duke Cancer Institute, Durham, North Carolina, USA

    Urologists have been using oral nonsteroidal antiandrogens (AA) for 30 years as a component of combined androgen blockade. In February 2018, a new third generation AA, apalutamide, became available for the first time for non-metastatic (M0) castrate resistant prostate cancer (CRPC). Apalutamide was found to delay the presence of metastases (metastases free survival-MFS) by approximately 2 years versus placebo in M0 CRPC. While overall survival benefit has yet to be established, the MFS benefit is clinically meaningful and urology practices should be equipped to manage patients using this new oral agent. Since the majority of patients remain under urologic care when this disease stage develops and because the drug is straightforward to administer, urology practices are ideal to identify and treat. The objective of this brief article is to discuss the typical patient profile for use of apalutamide and to review the pros and cons of use and common side effects and management.

    Keywords: prostate cancer, apalutamide, castrate-resistant, non-metastatic disease, antiandrogen,

    Jun 2019 (Vol. 26, Issue 3, Page 9782)
First Prev Page 1 of 1 Next Last

Current Issue

October 2019, Vol.26 No.5
canadian journal of urology